全文获取类型
收费全文 | 268篇 |
免费 | 13篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
妇产科学 | 3篇 |
基础医学 | 14篇 |
口腔科学 | 3篇 |
临床医学 | 24篇 |
内科学 | 143篇 |
皮肤病学 | 4篇 |
神经病学 | 5篇 |
特种医学 | 5篇 |
外科学 | 55篇 |
综合类 | 4篇 |
预防医学 | 3篇 |
药学 | 5篇 |
中国医学 | 4篇 |
肿瘤学 | 8篇 |
出版年
2023年 | 3篇 |
2022年 | 8篇 |
2021年 | 24篇 |
2020年 | 5篇 |
2019年 | 21篇 |
2018年 | 24篇 |
2017年 | 11篇 |
2016年 | 6篇 |
2015年 | 7篇 |
2014年 | 15篇 |
2013年 | 14篇 |
2012年 | 17篇 |
2011年 | 17篇 |
2010年 | 13篇 |
2009年 | 9篇 |
2008年 | 10篇 |
2007年 | 10篇 |
2006年 | 14篇 |
2005年 | 9篇 |
2004年 | 7篇 |
2003年 | 6篇 |
2002年 | 6篇 |
2001年 | 3篇 |
2000年 | 5篇 |
1998年 | 4篇 |
1997年 | 3篇 |
1995年 | 4篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1990年 | 3篇 |
1987年 | 1篇 |
1984年 | 1篇 |
排序方式: 共有284条查询结果,搜索用时 15 毫秒
1.
Akshay Shetty Fanny Giron Mukul K. Divatia Muhammad I. Ahmad Sudha Kodali David Victor 《临床与转化肝病杂志(英文版)》2021,9(3):428-435
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohepatitis (NASH) has led to a 170% increase in NASH cirrhosis as the listing indication for liver transplantation from 2004 to 2013. As of 2018, NASH has overtaken hepatitis C as an indication for liver transplantation in the USA. After liver transplantation, the allograft often develops recurrent NAFLD among patients with known NASH cirrhosis. In addition to recurrent disease, de novo NAFLD has been reported in patients with other indications for liver transplantation. In this review, we will discuss the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation. 相似文献
2.
Mayra Guerrero Amit Pursnani Akhil Narang Michael Salinger Dee Dee Wang Mackram Eleid Susheel K. Kodali Isaac George Lowell Satler Ron Waksman Christopher U. Meduri Vivek Rajagopal Ignacio Inglessis Igor Palacios Mark Reisman Marvin H. Eng Hyde M. Russell Ashish Pershad Charanjit Rihal 《JACC: Cardiovascular Interventions》2021,14(8):859-872
ObjectivesThe aim of this study was to assess 1-year clinical outcomes among high-risk patients with failed surgical mitral bioprostheses who underwent transseptal mitral valve-in-valve (MViV) with the SAPIEN 3 aortic transcatheter heart valve (THV) in the MITRAL (Mitral Implantation of Transcatheter Valves) trial.BackgroundThe MITRAL trial is the first prospective study evaluating transseptal MViV with the SAPIEN 3 aortic THV in high-risk patients with failed surgical mitral bioprostheses.MethodsHigh-risk patients with symptomatic moderate to severe or severe mitral regurgitation (MR) or severe mitral stenosis due to failed surgical mitral bioprostheses were prospectively enrolled. The primary safety endpoint was technical success. The primary THV performance endpoint was absence of MR grade ≥2+ or mean mitral valve gradient ≥10 mm Hg (30 days and 1 year). Secondary endpoints included procedural success and all-cause mortality (30 days and 1 year).ResultsThirty patients were enrolled between July 2016 and October 2017 (median age 77.5 years [interquartile range (IQR): 70.3 to 82.8 years], 63.3% women, median Society of Thoracic Surgeons score 9.4% [IQR: 5.8% to 12.0%], 80% in New York Heart Association functional class III or IV). The technical success rate was 100%. The primary performance endpoint in survivors was achieved in 96.6% (28 of 29) at 30 days and 82.8% (24 of 29) at 1 year. Thirty-day all-cause mortality was 3.3% and was unchanged at 1 year. The only death was due to airway obstruction after swallowing several pills simultaneously 29 days post-MViV. At 1-year follow-up, 89.3% of patients were in New York Heart Association functional class I or II, the median mean mitral valve gradient was 6.6 mm Hg (interquartile range: 5.5 to 8.9 mm Hg), and all patients had MR grade ≤1+.ConclusionsTransseptal MViV in high-risk patients was associated with 100% technical success, low procedural complication rates, and very low mortality at 1 year. The vast majority of patients experienced significant symptom alleviation, and THV performance remained stable at 1 year. 相似文献
3.
Stuart C. Gordon Therese M. Quattrociocchi-Longe Bilal A. Khan Valli P. Kodali Jenn Chen Ann L. Silverman Frederick L. Kiechle 《Gastroenterology》1995,108(6):1802-1809
Bile duct epithelia contain an abundance of carbonic anhydrase. Antibodies to this enzyme have been described in autoimmune disorders. Serum from patients with immune-mediated liver diseases was studied to determine whether antibodies to carbonic anhydrase II and/or pyruvate dehydrogenase could distinguish autoimmune cholangitis as immunologically distinct from primary biliary cirrhosis. Antibody assays to carbonic anhydrase II (Western blot) and pyruvate dehydrogenase (flow cytometry) were performed on the sera of patients with autoimmune cholangitis (6), primary biliary cirrhosis (12), primary sclerosing cholangitis (12), autoimmune hepatitis (12), and control (Gilbert syndrome; 8). Reactivity to carbonic anhydrase II was detected in 5 of 6 patients with autoimmune cholangitis, 1 of 12 patients with primary biliary cirrhosis, 1 of 12 patients with autoimmune hepatitis, and no other patients. Individuals with autoimmune cholangitis were more likely than the other patients to be reactive to carbonic anhydrase II (P < 0.001). Patients with primary biliary cirrhosis were more reactive to pyruvate dehydrogenase compared with all other groups (P < 0.001). An antibody to human carbonic anhydrase II is frequently detected in the sera of patients with autoimmune cholangitis and is uncommon or not present in other cholangiopathies. These data provide evidence that autoimmune cholangitis and primary biliary cirrhosis represent distinct entities with unique patterns of immunoreactivity. 相似文献
4.
Bahira Shahim S. Chris Malaisrie Isaac George Vinod H. Thourani Angelo B. Biviano Mark Russo David L. Brown Vasilis Babaliaros Robert A. Guyton Susheel K. Kodali Tamim M. Nazif Samir Kapadia Philippe Pibarot James M. McCabe Mathew Williams Philippe Genereux Michael Lu Xiao Yu Ioanna Kosmidou 《JACC: Cardiovascular Interventions》2021,14(14):1565-1574
ObjectivesThe aim of this study was to assess the incidence and prognostic impact of early and late postoperative atrial fibrillation or flutter (POAF) in patients with severe aortic stenosis (AS) treated with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR).BackgroundThere is an ongoing controversy regarding the incidence, recurrence rate, and prognostic impact of early (in-hospital) POAF and late (postdischarge) POAF in patients with AS undergoing TAVR or SAVR.MethodsIn the PARTNER (Placement of Aortic Transcatheter Valve) 3 trial, patients with severe AS at low surgical risk were randomized to TAVR or SAVR. Analyses were performed in the as-treated population excluding patients with preexistent atrial fibrillation or flutter.ResultsAmong 781 patients included in the analysis, early POAF occurred in 152 (19.5%) (18 of 415 [4.3%] and 134 of 366 [36.6%] following TAVR and SAVR, respectively). Following discharge, 58 new or recurrent late POAF events occurred within 1 year following the index procedure in 55 of 781 patients (7.0%). Early POAF was not an independent predictor of late POAF following discharge (odds ratio: 1.04; 95% CI: 0.52-2.08; P = 0.90). Following adjustment, early POAF was not an independent predictor of the composite outcome of death, stroke, or rehospitalization (hazard ratio: 1.10; 95% CI: 0.64-1.92; P = 0.72), whereas late POAF was associated with an increased adjusted risk for the composite outcome (hazard ratio: 8.90; 95% CI: 5.02-15.74; P < 0.0001), irrespective of treatment modality.ConclusionsIn the PARTNER 3 trial, early POAF was more frequent following SAVR compared with TAVR. Late POAF, but not early POAF, was significantly associated with worse outcomes at 2 years, irrespective of treatment modality. 相似文献
5.
Niharika Saw Joshua C. Vacanti Xiaoxia Liu Monica SaRego Hugh Flanagan Bhavani Shankar Kodali 《Journal of investigative surgery》2015,28(2):95-102
Purpose: On time start of the first surgical case improves operating room (OR) utilization, physician, and patient satisfaction and decreases delays in subsequent cases. The goal of our study was to evaluate the effect of a multidisciplinary initiative to improve first patient in the room (FPIR) and first case on time start (FCOTS) metrics in a tertiary care setting. Materials and Methods: A multidisciplinary committee focused on first case start data collection. Reasons for both anesthesia and surgical delays were analyzed. Improvement efforts focused on the timely completion of surgical consent, a requirement of a surgical, anesthesia, and nurse team member presence at the patient's bedside by specific time, and parallel processing in the OR. Results: Over 65,100 OR cases were analyzed between 2007 and 2014. There was a statistically significant improvement in FPIR (82.80% versus 69.60%, p < .0001) and FCOTS (66.60% versus 55.90%, p < .0001). Surgical consent completion rate increased from 35% baseline to 68%–100%, depending on the surgical subspecialty. Improvements appeared sustainable several years following process implementation for both FPIR (84.60% versus 69.60%, p < .0001) and FCOTS (67.60% versus 55.90%, p < .0001). Conclusions: Our study demonstrates a successful targeted, multidisciplinary initiative to improve first case surgical starts in an academic setting. Our approach was organizational rather than punitive or rewarding on an individual basis. Strategies included establishing concrete, time-specific goals and posting them visibly, empowering individuals to fulfill them, and ensuring no compromise in patient safety. In the complex environment of academic medicine including research protocols and teaching in the ORs, our organizational approach proved sustainable over several years. 相似文献
6.
Procedural variation in the performance of primary percutaneous coronary intervention for ST‐elevation myocardial infarction: A SCAI‐based survey study of US interventional cardiologists
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Austin Chiang MD Hemal Gada MD MBA Susheel K. Kodali MD Michael S. Lee MD Allen Jeremias MD Duane S. Pinto MD MPH Sripal Bangalore MD MHA Robert W. Yeh MD MSc Timothy D. Henry MD Georgina Lopez‐Cruz BS MSHA Roxana Mehran MD Ajay J. Kirtane MD SM 《Catheterization and cardiovascular interventions》2014,83(5):721-726
7.
8.
D. Scott Lim MD Robert L. Smith MD Firas Zahr MD Abhijeet Dhoble MD Roger Laham MD Mohamad Lazkani MD Susheel Kodali MD Chad Kliger MD James Hermiller MD Amit Vora MD Ian J. Sarembock MB ChB MD William Gray MD Samir Kapadia MD Adam Greenbaum MD Andrew Rassi MD David Lee MD Adnan Chhatriwalla MD Pinak Shah MD Josep Rodés-Cabau MD Homam Ibrahim MD Lowell Satler MD Howard C. Herrmann MD Paul Mahoney MD Charles Davidson MD George Petrossian MD Mayra Guerrero MD Konstantinos Koulogiannis MD Leo Marcoff MD Linda Gillam MD The CLASP IID Pivotal Trial Investigators 《Catheterization and cardiovascular interventions》2021,98(4):E637-E646
9.
Characterization of a voltage-gated K+ channel beta subunit expressed in human heart. 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
S K England V N Uebele H Shear J Kodali P B Bennett M M Tamkun 《Proceedings of the National Academy of Sciences of the United States of America》1995,92(14):6309-6313
Voltage-gated K+ channels are important modulators of the cardiac action potential. However, the correlation of endogenous myocyte currents with K+ channels cloned from human heart is complicated by the possibility that heterotetrameric alpha-subunit combinations and function-altering beta subunits exist in native tissue. Therefore, a variety of subunit interactions may generate cardiac K+ channel diversity. We report here the cloning of a voltage-gated K+ channel beta subunit, hKv beta 3, from adult human left ventricle that shows 84% and 74% amino acid sequence identity with the previously cloned rat Kv beta 1 and Kv beta 2 subunits, respectively. Together these three Kv beta subunits share > 82% identity in the carboxyl-terminal 329 aa and show low identity in the amino-terminal 79 aa. RNA analysis indicated that hKv beta 3 message is 2-fold more abundant in human ventricle than in atrium and is expressed in both healthy and diseased human hearts. Coinjection of hKv beta 3 with a human cardiac delayed rectifier, hKv1.5, in Xenopus oocytes increased inactivation, induced an 18-mV hyperpolarizing shift in the activation curve, and slowed deactivation (tau = 8.0 msec vs. 35.4 msec at -50 mV). hKv beta 3 was localized to human chromosome 3 by using a human/rodent cell hybrid mapping panel. These data confirm the presence of functionally important K+ channel beta subunits in human heart and indicate that beta-subunit composition must be accounted for when comparing cloned channels with endogenous cardiac currents. 相似文献
10.